Citations

Clear

16280 citation(s) found for "Yu, David".

Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
Bajaj, Jasmohan S. , Reddy, K. Rajender , Keaveny, Andrew P. , Porayko, Michael K. , Koch, David , Thuluvath, Paul J. , Angeli, Paolo, Janardhan, Sujit , Zhang, Jeffrey , Clausen, Susan, Dauphinée, Elisa, Palumbo, Joseph, Markham, Penelope , Weinberg, Ethan M , Rajender Reddy, K , Keaveny, Andrew P , Porayko, Michael K , Koch, David , Angeli, Paolo , Orman, Eric S , Palumbo, Joseph M , Weinberg, Ethan M. , Simonetto, Douglas A. , Angeli, Paolo , Orman, Eric S. , Clausen, Susan

Mayo Clinic

Liver Transplantation | April 24, 2025 | Volume: 31 | Issue: 10 | Pages: 1202-1214

10.1097/lvt.0000000000000623 | PMID 40272365 Get It

Refractory ascites often requires therapeutic paracentesis, which is associated with potential risks and diminished quality of life. Terlipressin is a vasopressin analog that is indicated for i.v. bolus injection for hepatorenal syndrome, with the potential to reduce large-volume ascites and its complications. Continuous infusion of terlipressin is associated with fewer adverse effects than bolus dosing. The efficacy and safety of continuous infusion of a novel liquid formulation of terlipressin acetate (BIV201) were evaluated in this open-label phase 2 study. Patients with cirrhosis and refractory ascites were randomly assigned (2:1) to receive two 28-day cycles of continuous infusion BIV201 plus standard of care (SOC) separated by a ≤56-day washout (n=10), or SOC alone (n=5). Data analysis was limited by the small sample size and confounded by a potential interaction with gabapentinoids in the BIV201+SOC group. Nonetheless, there were differences in favor of BIV201+SOC versus SOC in the coprimary efficacy endpoints and several quality of life assessments. The beneficial effects of BIV201 on liver complications (mean: 90% CI; BIV201-completers=2.87: 1.51; 5.46 vs. SOC=2.38: 1.20; 4.73) and the change in cumulative ascites (mean: 90% CI; BIV201-completers=−10.76: −26.51; 5.00 vs. SOC=−4.99: −21.95; 11.97) were more pronounced versus SOC in the 5 BIV201+SOC patients who completed both treatment cycles. There were also greater improvements in exploratory quality of life assessments and the percent change in therapeutic paracenteses with BIV201+SOC (−27.94±41.80) versus SOC (−16.67±45.64). Despite the high rate of hyponatremia in the BIV201+SOC group (4/10 patients), the safety profile suggested that continuous BIV201 infusion was well tolerated. These findings support further development of BIV201 in confirmatory trials.
Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute
Levine, Deborah J. , Castillo, Howard, Arcasoy, Selim M. , Benvenuto, Luke , Cevasco, Marisa , Demarest, Caitlin T. , Dewachter, Céline , Erasmus, Michiel E. , Glanville, Allan R. , Granton, John , Khangoora, Vikramjit, Krishnan, Sheila , Miltiades, Andrea , Murphy, Edward L. , Robbins, Ivan M. , Rahaghi, Franck , Saddoughi, Sahar A. , Vachiéry, Jean-Luc, Whitford, Helen, Girgis, Reda E. , Kolaitis, Nicholas A , Arcasoy, Selim M , Mercier, Olaf , Montani, David , Robbins, Ivan , Barnes, Hayley , Bacchetta, Matthew , Rosenzweig, Erika B. , Keshavjee, Shaf , Saddoughi, Sahar A. , Savale, Laurent , Simon, Marc A. , Vachiéry, Jean‐Luc , Ventetuolo, Corey E.

Mayo Clinic

Pulmonary Circulation | April 24, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70088 | PMID 40276473 Get It

ABSTRACTLung transplantation is indicated for selected patients with advanced pulmonary arterial hypertension (PAH). We used a modified Delphi process to develop recommendations on care of patients with PAH undergoing lung transplantation. This Delphi panel was recruited from the Pulmonary Vascular Research Institute's Innovative Drug Discovery Initiative ‐ Lung Transplantation Workstream, consisting of clinical and research experts in PAH and lung transplantation. In this process, 29 panelists were given open‐ended questions, querying topics related to lung transplantation in PAH. A steering group converted the responses into discrete statements. Panelists then rated agreement using a Likert scale in two further survey rounds: −5 (strongly disagree) to 5 (strongly agree). Consensus was defined as mean ≥ 2.5 or ≤ −2.5, with a standard deviation not crossing zero. Consensus was reached on 141 of 223 statements. Notable areas of consensus were for early discussions about transplantation, and agreement with previously published referral and listing criteria. There was agreement that lung transplantation could be offered in sick candidates, including those with concurrent renal or hepatic insufficiency. Bilateral lung transplantation was considered the procedure of choice for most patients, with rare indications for heart‐lung transplantation. Consensus on bridging strategies included use of veno‐arterial extracorporeal membrane oxygenation and preemptive awake cannulation in those with severe right ventricular dysfunction. Consensus was also achieved on intraoperative use of invasive hemodynamic monitoring, and prolonged postoperative circulatory support guided by hemodynamic response and echocardiography. Patients with PAH undergoing transplantation require specialized management, which differs somewhat from other candidates.
Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor
Nelson, Alexander T. , Watson, David , Chen, Kenneth , Olson, Damon R. , Stall, Jennifer N., Devins, Kyle M. , Young, Robert H. , Kamihara, Junne , Mallinger, Paige, Kim, Jung , Hatton, Jessica N. , Schneider, Dominik T. , Harris, Anne K. , Dehner, Louis P. , Schultz, Kris Ann P. , Watson, Dave , Chen, Kenneth S , Mallinger, Paige H R , Messinger, Yoav H , Frazier, A Lindsay , Stewart, Douglas R , Harris, Anne K , Dehner, Louis P , Hill, Dana Ashley , Schultz, Kris Ann P , Olson, Damon R , Schneider, Dominik T , Devins, Kyle M , Messinger, Yoav H.

Mayo Clinic

JCO Precision Oncology | April 23, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00902 | PMID 40267387 Get It

PURPOSE Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, representing <0.5% of all ovarian tumors. We analyze the role of germline DICER1 status in outcomes of ovarian SLCT. METHODS Patients with SLCT were enrolled in the International Pleuropulmonary Blastoma/ DICER1 Registry and/or the International Ovarian and Testicular Stromal Tumor Registry. Medical records were systematically abstracted, and those with known germline DICER1 status were selected for analysis. RESULTS Of 162 patients with SLCT, 60% had a germline DICER1 pathogenic or likely pathogenic (P/LP) variant. The adjusted 3-year recurrence-free survival (RFS) was 87.2% (95% CI, 79.4 to 95.8) for patients with a germline DICER1 P/LP variant compared with 78.1% (95% CI, 66.4 to 91.9) for those without a germline DICER1 P/LP variant ( P = .043). The adjusted 3-year and 5-year overall survival (OS) was 93.9% (95% CI, 87.3 to 100.0) for those with a germline DICER1 P/LP variant compared with the 3-year OS of 91.3% (95% CI, 83.4 to 100.0) and the 5-year OS of 78.2% (95% CI, 63.8 to 95.9) for those without a germline DICER1 P/LP variant ( P = .021). Among patients with a germline DICER1 P/LP variant, the risk of a subsequent, nonrecurrent event was 36.2% (95% CI, 21.4 to 48.1) within 10 years. Previous/concurrent and subsequent neoplasms were rare among those without a germline DICER1 P/LP variant. CONCLUSION This cohort study of patients with SLCT demonstrated that those with germline DICER1 P/LP variants had superior RFS and OS even when adjusting for other prognostic factors. Beyond prognostic implications of a germline DICER1 P/LP variant, germline testing helps identify patients at risk of subsequent neoplasms, including metachronous SLCT.
Deep Learning Model for Histologic Diagnosis of Dysplastic Barrett's Esophagus: Multisite Cohort External Validation
Codipilly, Don C. , Faghani, Shahriar , Vogelsang, David C. , Erickson, Bradley J. , Garg, Nikita , Lewis, Jason , Leggett, Cadman L. , Konda, Vani J. , Diffalha, Sameer Al , Peter, Shajan, Brinkerhoff, Brian , Wong, Mary , Otaki, Fouad , Katzka, David A. , Wani, Sachin , Shaheen, Nicholas J. , Iyer, Prasad G. , Codipilly, Don Chamil , Vogelsang, David, Erickson, Bradley J , Hagen, Catherine E , Leggett, Cadman L , Konda, Vani , Wong, Mary , Otaki, Fouad , Katzka, D A , Faghani, Shahriar , Hagen, Catherine E. , Patil, Pallavi

Mayo Clinic

American Journal of Gastroenterology | April 23, 2025 | Volume: 121 | Issue: 4 | Pages: 863-870

10.14309/ajg.0000000000003495 | PMID 40267276 Get It

INTRODUCTION: The risk of progression to esophageal adenocarcinoma in Barrett's esophagus (BE) increases with advancing degrees of dysplasia. There is a critical need to improve the diagnosis of BE dysplasia, given substantial interobserver variability and overcalls of dysplasia during manual community pathologist reads. We aimed to externally validate a previously cross-validated BE dysplasia diagnosis deep learning model (BEDDLM) that predicts dysplasia grade on whole slide images (WSIs). METHODS: We digitized nondysplastic BE (NDBE), low-grade (LGD), and high-grade dysplasia (HGD) histology slides from 3 external academic centers. A consensus read by 2 expert study pathologists was used as the criterion standard. Slide stain characteristics were normalized using cycle-generative adversarial networks. WSIs were assessed by BEDDLM using an ensemble approach, combining a “You Only Look Once” model followed by a ResNet101 classifier model. RESULTS: We included 489 WSIs. Consensus histopathology revealed 232 NDBE, 117 LGD, and 140 HGD WSIs. The mean age (SD) was 66.9 (11.4) years; 413 (84.7%) were men. Using the BEDDLM ensemble model, sensitivity and specificity for NDBE were 73.3% (95% confidence interval [CI]: 67.09%–78.85%) and 93.4% (95% CI: 89.62%–96.10%); for LGD, 84.6% (95% CI: 76.78%–90.62%) and 80.6% (95% CI: 76.26%–84.54%); and for HGD, 80.7% (95% CI: 73.19%–86.89%) and 94.8% (95% CI: 91.97%–96.91%), respectively. The F1 score was 0.81, 0 0.69, and 0.83 for NDBE, LGD, and HGD, respectively. DISCUSSION: Our externally validated deep learning model demonstrates substantial accuracy for the diagnosis of BE dysplasia grade on WSIs.
Spatially convergent fMRI signatures of diabetes and male sex identify genetic vulnerabilities to accelerated brain aging
Chesebro, Anthony G. , Rohm, Luna R., Antal, Botond , Weistuch, Corey , Strey, Helmut H. , Ratai, Eva‐Maria , Mujica‐Parodi, Lilianne R. , Mujica-Parodi, Lilianne R , Jones, David T.

Mayo Clinic

No container title available | April 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.14.648801 Get It

Abstract Age-related cognitive decline results from complex interactions between neuroendocrine and neurometabolic processes that undergo lifelong degredation, yet the mechanisms underlying these interactions remain poorly understood. This study examined the effects of diabetes and sex on functional brain networks across aging through analysis of two large cohorts (N=1,621 total) using both 3T and 7T functional MRI, complemented by spatial transcriptomic data from over 14,000 genes from six post-mortem brains. Four networks— cingulo-opercular, default mode, salience, and lateral somatomotor—exhibited significant functional decline in both individuals with diabetes and independently in males. Gene expression analysis of vulnerable networks revealed significant overexpression of insulin-dependent glucose transporters, dopaminergic and GABAergic synaptic genes, and VEGFA-VEGFR2 pathway components. These findings suggest functionally-specific circuit vulnerability to metabolic and hormonal dysregulation, potentially offering targets for early intervention before irreversible neurodegeneration occurs.
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy for prevention of recurrent Clostridioides difficile infectio
Khanna, Sahil , Yoho, David, Handel, Daniel Van, Clark, Brian J., Awad, Tahany , Guthmueller, Beth, Armandi, Daniel, Knapple, W , Safdar, Nasia , Baggott, Brian, Simon, Karen, Knapple, Whitfield , Feuerstadt, Paul , Feuerstadt, Paul

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 23, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251339697 | PMID 40321366 Get It

Background: Recurrent Clostridioides difficile infection (rCDI) occurs in up to 35% of patients with CDI, and further recurrence is common. Fecal microbiota, live-jslm (RBL) is safe and effective for preventing rCDI in adults following antibiotic treatment for rCDI when administered rectally. There is clinical interest in alternative routes of administration. Objectives: CDI-SCOPE assessed the safety and clinical effectiveness of RBL when administered via colonoscopy to adults with rCDI. Design: Single-arm, exploratory phase IIIb trial conducted at 12 sites in the United States. Methods: Eligible adults with rCDI received one administration of RBL consisting of one 150-mL dose of RBL, delivered via colonoscopy to the right side of the colon. The primary endpoint assessed RBL-related treatment-emergent adverse events (TEAEs) within 8 weeks of RBL administration or until confirmed treatment failure. Secondary endpoints included treatment success (absence of CDI recurrence for 8 weeks following RBL administration), physician experience administering RBL via colonoscopy, and physician perception of participant benefit. Results: Of 54 participants screened, 41 were enrolled and received RBL via colonoscopy; 39 participants completed the 8-week visit. Five TEAEs in four participants (9.8%) were assessed as related to RBL, all of which were gastrointestinal and mild in severity. Overall, 18 participants (43.9%) experienced 33 TEAEs within 8 weeks, most of which were of mild (25/33; 75.8%) or moderate (5/33; 15.2%) severity. No TEAEs led to intensive care unit admission or death. Overall, 39 participants (95.1%) experienced treatment success; 2 participants (4.9%) withdrew consent and had an indeterminate outcome. Among physicians, 90.2% of investigators indicated a “positive” or “very positive” experience administering RBL by colonoscopy. All physicians assessed participant benefit as “much” or “very much” improved. Conclusion: This single-arm study suggests RBL administered via colonoscopy is practical, safe, and effective for preventing CDI recurrence following antibiotic treatment in adults. Trial registration: ClinicalTrials.gov: NCT05831189.
Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID : A compendium statement
Cheng, Abby L. , Herman, Eric, Abramoff, Benjamin , Anderson, Jordan , Baratta, John M. , Bartels, Matthew N. , Bhavaraju‐Sanka, Ratna, Fine, Jeffrey S., Herrera, Joseph E., Karnik, Rasika, Kurylo, Monica, Longo, Michele, McCauley, Mark , Melamed, Esther , Miglis, Mitchell G. , Neal, Jacqueline D., Oleson, Christina V. , Rydberg, Leslie , Terzic, Carmen M., Niehaus, William , Baratta, John M , Fleming, Talya K , Verduzco-Gutierrez, Monica , Rydberg, Leslie , Silver, Julie , Miglis, Mitchell G , Azola, Alba Miranda , Blitshteyn, Svetlana , Fleming, Talya K. , Verduzco‐Gutierrez, Monica , Putrino, David F. , Silver, Julie K. , Whiteson, Jonathan H.

Mayo Clinic

PM&R | April 22, 2025 | Volume: 17 | Issue: 6 | Pages: 684-708

10.1002/pmrj.13397 | PMID 40261198 Get It

Abstract Background In 2021, the American Academy of Physical Medicine and Rehabilitation established the Multi‐Disciplinary Post‐Acute Sequelae of SARS‐CoV‐2 Infection Collaborative to provide guidance from established Long COVID clinics for the evaluation and management of Long COVID. The collaborative previously published eight Long COVID consensus guidance statements using a primarily symptom‐based approach. However, Long COVID symptoms most often do not occur in isolation. Aims This compendium aims to equip clinicians with an efficient, up‐to‐date clinical resource for evaluating and managing adults experiencing Long COVID symptoms. The primary intended audience includes physiatrists, primary care physicians, and other clinicians who provide first‐line assessment and management of Long COVID symptoms, especially in settings where subspecialty care is not readily available. This compendium provides a holistic framework for assessment and management, symptom‐specific considerations, and updates on prevalence, health equity, disability considerations, pathophysiology, and emerging evidence regarding treatments under investigation. Because Long COVID closely resembles other infection‐associated chronic conditions (IACCs) such as myalgic encephalomyelitis/chronic fatigue syndrome, the guidance in this compendium may also be helpful for clinicians managing these related conditions. Methods Guidance in this compendium was developed by the collaborative's established modified Delphi approach. The collaborative is a multidisciplinary group whose members include physiatrists, primary care physicians, pulmonologists, cardiologists, psychiatrists, neuropsychologists, neurologists, occupational therapists, physical therapists, speech and language pathologists, patients, and government representatives. Over 40 Long COVID centers are represented in the collaborative. Results Long COVID is defined by the National Academies of Sciences, Engineering, and Medicine as “an IACC that occurs after SARS‐CoV‐2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems.” The current global prevalence of Long COVID is estimated to be 6%. Higher prevalence has been identified among female gender, certain racial and ethnic groups, and individuals who live in nonurban areas. However, anyone can develop Long COVID after being infected with the SARS‐CoV‐2 virus. Long COVID can present as a wide variety of symptom clusters. The most common symptoms include exaggerated fatigue and diminished energy windows, postexertional malaise (PEM)/postexertional symptom exacerbation (PESE), cognitive impairment (brain fog), dysautonomia, pain/myalgias, and smell and taste alterations. Holistic assessment should include a traditional history, physical examination, and additional diagnostic testing, as indicated. A positive COVID‐19 test during acute SARS‐CoV‐2 infection is not required to diagnose Long COVID, and currently, there is no single laboratory finding that is definitively diagnostic for confirming or ruling out the diagnosis of Long COVID. A basic laboratory assessment is recommended for all patients with possible Long COVID, and consideration for additional labs and diagnostic procedures is guided by the patient's specific symptoms. Current management strategies focus on symptom‐based supportive care. Critical considerations include energy conservation strategies and addressing comorbidities and modifiable risk factors. Additionally, (1) it is essential to validate the patient's experience and provide reassurance that their symptoms are being taken seriously because many patients have had their symptoms dismissed by loved ones and clinicians; (2) physical activity recommendations must be carefully tailored to the patient's current activity tolerance because overly intense activity can trigger PEM/PESE and worsened muscle damage; and (3) treatment recommendations should be delivered with humility because there are many persistent unknowns related to Long COVID. To date, there are limited data to guide medication management specifically in the context of Long COVID. As such, medication use generally follows standard practice regarding indications and dosing, with extra attention to prioritize (1) patient preference via shared decision‐making and (2) cautious use of medications that may improve some symptoms (eg, cognitive/attention impairment) but may worsen other symptoms (eg, PEM/PESE). Numerous clinical trials are investigating additional treatments. The return‐to‐work process for individuals with Long COVID can be challenging because symptoms can fluctuate, vary in nature, affect multiple functional areas (eg, physical and cognitive), and often manifest as an “invisible disability” that may not be readily acknowledged by employers or coworkers. Clinicians can help patients return to work by identifying suitable workplace accommodations and resources, providing necessary documentation, and recommending occupational or vocational therapy when needed. If these efforts are unsuccessful and work significantly worsens Long COVID symptoms or impedes recovery, applying for disability may be warranted. Long COVID is recognized as a potential disability under the Americans with Disabilities Act. Conclusion To contribute to the overall health and well‐being for all patients, Long COVID care should be delivered in a holistic manner that acknowledges challenges faced by the patient and uncertainties in the field. For more detailed information on assessment and management of specific Long COVID symptoms, readers can reference the collaborative's symptom‐specific consensus guidance statements.
Emerging babesiosis in the mid-Atlantic: autochthonous human babesiosis cases and Babesia microti (Piroplasmida: Babesiidae) in Ixodes scapularis (Acari: Ixodidae
Stromdahl, Ellen Y. , Feldman, Katherine A. , Nadolny, Robyn M. , Kennedy, Ashley C. , Bement, Zachary , Buoni, Michael , Rutz, Heather , Broyhill, James, Bernick, Joshua, Brinkerhoff, R. Jory , Ayuk-Takor, Leslie, Crum, David A., Dotseth, Eric J., Flammia, Lori, Girone, Kyle, Gaines, David N., Phan, Anna , Wee, Siok-Bi, Gaff, Holly , Hynes, Wayne L. , Bement, Zachary J , Gaff, Holly D , Hynes, Wayne L , Bernick, Joshua, Ayuk-Takor, Leslie, Silva, Alexandre J. da , Pritt, Bobbi S.

Mayo Clinic

Journal of Medical Entomology | April 22, 2025 | Volume: 62 | Issue: 4 | Pages: 995-1008

10.1093/jme/tjaf054 | PMID 40261095 Get It

Abstract The range of Babesia microti (Franca, 1910)-infected ticks is expanding, resulting in locally acquired human babesiosis cases occurring in new areas: Maryland (2009), the District of Columbia (2013), Virginia (2016), and West Virginia (2017). We collected host-seeking ticks from old fields, ecotones, forested habitats and animal hosts in Delaware, Maryland, and Virginia, 2010 to 2024. Ixodes scapularis Say, the tick vector of babesiosis, was captured in all 3 states. PCR revealed B. microti in 2.7% (36/1310) of I. scapularis, with site prevalence ranging from &lt;1% to 12.5% infected. The first B. microti-positive I. scapularis was collected in Northampton County, Virginia, 2012. Of the B. microti-infected ticks, 50% (18/36) were coinfected with Borrelia burgdorferi and one was triple-infected with B. microti, B. burgdorferi, and Anaplasma phagocytophilum. We collected Ixodes keiransi Beati, Nava, Venzal, and Guglielmone ticks from Delaware and Virginia. We found B. microti and B. burgdorferi in those from Virginia, and B. burgdorferi in ticks from a shrew in Delaware. To our knowledge, this is the first report of B. microti and B. burgdorferi-positive I. keiransi from Virginia, and the first report of B. burgdorferi-positive I. keiransi from Delaware. Ixodes keiransi ticks rarely bite humans but are involved in the maintenance and spread of pathogens when sympatric with I. scapularis. We tested a subset of both tick species for Babesia duncani; none were positive. Jurisdictions in the southern mid-Atlantic region should expect babesiosis cases, and Lyme disease and anaplasmosis coinfections, and healthcare providers should consider these tick-borne infections as part of the differential diagnosis.
Bioartificial liver support for acute liver failure
Nelson, Erek , Chen, Harvey , Amiot, Bruce , Nyberg, Scott L. , Nelson, Erek David , Nyberg, Scott L , Joo, Dong Jin

Mayo Clinic

Annals of Liver Transplantation | April 22, 2025 | Volume: 5 | Issue: 1 | Pages: 31-39

10.52604/alt.25.0004 Get It